ESPE Abstracts (2014) 82 P-D-3-1-811

ESPE2014 Poster Category 3 Growth (14 abstracts)

A Novel GHR Mutation, c.439+1g>a; in a Family with Laron Syndrome

Mona Attia a , Atef Abeer a , Ibrahim Makarem c , Malcolm Donaldson d , Lou Metherell e , Sameh Tawfik b & Wafaa Dowedar b


aCairo University, Cairo, Egypt; bMaadi, Cairo, Egypt; cMinistry of Health, Cairo, Egypt; dYorkhill, Glasgow, UK; eQueen Mary University, London, UK


Background: Mutations in the human GH receptor gene (GHR) are the most common cause of GH insensitivity (GHI) syndrome and IGF1 deficiency. The extracellular domain of GHR (encoded by exons 2–7 of the GHR gene) can be proteolytically cleaved to circulate as GH-binding protein.

Objective: To evaluate the cause of classical GHI (Laron) phenotypes in two siblings and their parents.

Method: We observed clinical characteristics of two sibs with extreme short stature, assessed the function of GH–IGF1 axis, and surveyed their parents. Genomic DNA was extracted from peripheral blood, GHR mutation gene was amplified by PCR for sequencing, including exons and splicing areas.

Results: Two full term brothers with average birth weight (aged 9.4 and 6.23 years) presented with extreme short stature. Height SDS, SDS, was (−6.42 and −5.50 S.D. respectively). The parents were consanguineous with normal stature (mother 156 cm, father 165 cm). Children’s weight: −5.49 and −2.81 S.D. respectively). Chronological age–bone age(−5.2 and −2.53 years respectively). Peak GH for the two sibs; by glucagon was 33.3 and 15.7 ng/ml respectively. IGF1 for the older brother was: 9.5, 23.8, and 18.2 ng/ml; while IGF1 for the younger was: 18.1, 28.6, and 22.2 ng/ml; during IGF-1 generation test (reference range 98–156 ng/ml).

Mutation: The two brothers were homozygous GHR mutation c.439+1G>A, so a splice site mutation at the junction of exon 5/intron 5. It’s novel and would be predicted to lead to skipping of exon 5, a frameshift and premature truncation of the protein also both parents were heterozygous for the same mutation.

Conclusion: The clarification of the molecular genetics for these defects will contribute to our future understanding of both normal and aberrant growth and avoid miss-diagnosis and mal-treatment.

Volume 82

53rd Annual ESPE (ESPE 2014)

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.